Multiple Myeloma Today: Navigating a Shifting Treatment Landscape
EP. 1: Setting the Stage: The Most Significant Shifts in Frontline Multiple Myeloma Treatment
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Tiffany Richards, PhD, APRN, ANP-BC, AOCNP,Jackson Gao, MD,Tyler Sandahl, PharmD Experts unpack new myeloma regimens—quadruplet induction, dual maintenance, earlier smoldering therapy—plus real-world access and cost hurdles.
EP. 2: From Satisfaction to Solutions: Unmet Needs, Future Regimens, and Anti-CD38 Formulary Management in NDMM
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Tiffany Richards, PhD, APRN, ANP-BC, AOCNP,Jackson Gao, MD,Tyler Sandahl, PharmD The panelists examined the significant progress made in frontline multiple myeloma treatment while emphasizing that true satisfaction will only come when more patients achieve a durable cure and can transition off maintenance therapy entirely, identifying MRD-guided treatment discontinuation as one of the most promising pathways toward that goal.
EP. 3: Patient-Centered Frontline Decisions: Regimen Selection, Frailty Assessment, and High-Risk NDMM Management
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Tiffany Richards, PhD, APRN, ANP-BC, AOCNP,Jackson Gao, MD,Tyler Sandahl, PharmD Experts weigh quadruplet vs triplet myeloma therapy, tailoring to frailty and clots, and push early CAR-T/BCMA options for high-risk patients.
EP. 4: From Trial Data to Clinical Practice: DVRd, MRD Testing, and Payer Coverage Considerations in NDMM
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Tiffany Richards, PhD, APRN, ANP-BC, AOCNP,Jackson Gao, MD,Tyler Sandahl, PharmD Experts debate quadruplet myeloma therapy, MRD-guided de-escalation, and risk-adapted intensification—plus how payers may respond.
EP. 5: CEPHEUS at 6 Years: Counseling Transplant-Ineligible Patients and Managing DVRd in Frail Populations
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Tiffany Richards, PhD, APRN, ANP-BC, AOCNP,Jackson Gao, MD,Tyler Sandahl, PharmD Cepheus data shows durable 6‑year control with DVRd, prompting new counseling and tailored dosing for frail, transplant‑ineligible myeloma patients.
EP. 6: Examining BelaDRd, BCMA Targeting, and Contextualizing Early MRD Data
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Tiffany Richards, PhD, APRN, ANP-BC, AOCNP,Jackson Gao, MD,Tyler Sandahl, PharmD BCMA ADC belantamab added to DRd shows striking MRD negativity in early myeloma trials, but eye toxicity and access shape frontline use.
EP. 7: MRD Negativity as a Benchmark: Testing Approaches, Treatment Implications, and the Evolving Role of Response Depth
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Tiffany Richards, PhD, APRN, ANP-BC, AOCNP,Jackson Gao, MD,Tyler Sandahl, PharmD Experts discuss how MRD testing in myeloma increasingly guides frontline care, yet unanswered questions still limit using MRD as the sole benchmark.
EP. 8: Navigating Costs in NDMM: Key Considerations and What Influences Decision-Making
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Tiffany Richards, PhD, APRN, ANP-BC, AOCNP,Jackson Gao, MD,Tyler Sandahl, PharmD Experts weigh meaningful innovation in frontline myeloma therapy against incremental gains, spotlighting patient out-of-pocket costs, financial counseling, and payer-driven formulary decisions.
EP. 9: First Relapse in Multiple Myeloma: Balancing Options, Sequencing Decisions, and Patient-Centered Care
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Tiffany Richards, PhD, APRN, ANP-BC, AOCNP,Jackson Gao, MD,Tyler Sandahl, PharmD Explore how experts personalize second-line myeloma care at first relapse, weighing CAR T, bispecifics, and evolving sequencing amid rapid approvals.
EP. 10: Refractory vs. Exposed: How Anti-CD38 Status Shapes Second-Line Treatment Decisions in Multiple Myeloma
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Tiffany Richards, PhD, APRN, ANP-BC, AOCNP,Jackson Gao, MD,Tyler Sandahl, PharmD Learn how daratumumab exposure vs refractoriness guides second-line myeloma therapy, and what MajesTEC trials suggest for BCMA bispecifics.
EP. 11: Teclistamab Plus Daratumumab: MajesTEC-3 Data, Patient Selection, and the Evolving Role of Bispecifics in RRMM
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Tiffany Richards, PhD, APRN, ANP-BC, AOCNP,Jackson Gao, MD,Tyler Sandahl, PharmD New myeloma data show teclistamab+daratumumab slashes relapse risk (HR 0.17), reshaping second-line choices beyond CAR T.
EP. 12: Bispecific Sequencing, CRS Risk, and CELMoDs: Navigating the Evolving Second-Line RRMM Landscape
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Tiffany Richards, PhD, APRN, ANP-BC, AOCNP,Jackson Gao, MD,Tyler Sandahl, PharmD Learn how myeloma experts sequence BCMA vs GPRC5D bispecifics, manage CRS with prophylactic tocilizumab, and plan for CELMoDs.
EP. 13: The Bispecific Antibody Evolution and the CAR-T Access Imperative
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Tiffany Richards, PhD, APRN, ANP-BC, AOCNP,Jackson Gao, MD,Tyler Sandahl, PharmD Experts weigh BCMA vs GPRC5D bispecifics
EP. 14: Beyond Clinical Efficacy: How Cost, Access, and Operational Challenges Influence RRMM Treatment Decisions
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Tiffany Richards, PhD, APRN, ANP-BC, AOCNP,Jackson Gao, MD,Tyler Sandahl, PharmD How cost, access and pharmacy logistics shape second-line relapse therapy—CAR T vs bispecifics—plus strategies to win coverage and cut care costs.
